This article has been updated to include a response from Ambry.

NEW YORK (GenomeWeb News) – Myriad Genetics and other assignees to several patents underlying the BRACAnalysis test have filed a patent infringement lawsuit in the US District Court for the District of Utah against Ambry Genetics.

The patent holders allege that Ambry's testing process for gauging mutations in BRCA1 and BRCA2 associated with breast and ovarian cancer risk infringe claims in 10 patents owned or licensed by them.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.